SLS — Sellas Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $289.16m
- $244.84m
- 47
- 17
- 84
- 47
Annual cashflow statement for Sellas Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.8 | -20.7 | -41.3 | -37.3 | -30.9 |
| Deferred Taxes | |||||
| Non-Cash Items | 0.773 | 2.53 | 1.85 | 2.58 | 2.13 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.59 | -7.62 | 15.6 | 3.35 | -6.65 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -10.4 | -26 | -23.8 | -31.4 | -35.4 |
| Capital Expenditures | — | — | -4.5 | -5.5 | 0 |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | — | — | -4.5 | -5.5 | 0 |
| Financing Cash Flow Items | — | — | 0.085 | -0.031 | -0.064 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 38.4 | 12.1 | 24.1 | 22.3 | 46.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28 | -13.9 | -4.23 | -14.6 | 11.4 |